Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc. is positioned favorably in the regenerative medicine sector through its expanding portfolio, particularly with Apligraf experiencing a fourfold increase in average selling price (ASP), establishing itself as a leader in efficacy among its product offerings. Despite facing mixed performance due to shifting market dynamics and potential changes in reimbursement structures, the company has demonstrated ongoing improvements in unit volumes, which indicates a trajectory towards stronger quarterly growth in the near future. Additionally, the adjustment in reimbursement rates for 2026, increasing slightly from the proposal, reflects a resilient pricing environment that could enhance the company's valuation and financial performance moving forward.

Bears say

Organogenesis Holdings Inc. has experienced a significant decline in its share price, dropping approximately 35% due to weaker-than-expected guidance for FY26, primarily driven by reimbursement policy changes in the Advanced Wound Care market. The company anticipates a substantial year-over-year decline of roughly 50% in 1Q26 as it undertakes measures to address product sizing waste and excess inventory. Additionally, potential downside risks include subpar growth in its PuraPly product line, adverse Medicare pricing developments, and competitive challenges related to regulatory integration and new product uptake, further contributing to a cautious outlook for the company.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.